An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Jamaican fruit bats support disseminated infection of Ebola but not Marburg virus. The differences in infection dynamics are partially attributable to Marburg’s less efficient entry and impaired ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

GSK shares are trading cheaply and offering potential passive income. So is this FTSE 100 stock a no-brainer buy for my ...